vs

Side-by-side financial comparison of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) and Vera Bradley, Inc. (VRA). Click either name above to swap in a different company.

Vera Bradley, Inc. is the larger business by last-quarter revenue ($62.3M vs $44.6M, roughly 1.4× PACIFIC BIOSCIENCES OF CALIFORNIA, INC.). Vera Bradley, Inc. runs the higher net margin — -19.9% vs -90.4%, a 70.6% gap on every dollar of revenue. On growth, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. posted the faster year-over-year revenue change (13.8% vs -22.7%). Vera Bradley, Inc. produced more free cash flow last quarter ($-4.5M vs $-19.9M). Over the past eight quarters, Vera Bradley, Inc.'s revenue compounded faster (16.1% CAGR vs 7.3%).

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

Vera Bradley Sales, LLC is an American luggage and handbag design company, founded by Barbara Bradley Baekgaard and Patricia R. Miller in 1982. As of 2019, its home office is in Fort Wayne, Indiana. The company was named after Baekgaard's mother. Its original luxury cotton bag product lines have expanded to include fashion and home accessories, office supplies, and patterned gifts. Many items have distinctive florals, paisleys, or geometric prints with complementary linings, as well as elonga...

PACB vs VRA — Head-to-Head

Bigger by revenue
VRA
VRA
1.4× larger
VRA
$62.3M
$44.6M
PACB
Growing faster (revenue YoY)
PACB
PACB
+36.6% gap
PACB
13.8%
-22.7%
VRA
Higher net margin
VRA
VRA
70.6% more per $
VRA
-19.9%
-90.4%
PACB
More free cash flow
VRA
VRA
$15.5M more FCF
VRA
$-4.5M
$-19.9M
PACB
Faster 2-yr revenue CAGR
VRA
VRA
Annualised
VRA
16.1%
7.3%
PACB

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
PACB
PACB
VRA
VRA
Revenue
$44.6M
$62.3M
Net Profit
$-40.4M
$-12.4M
Gross Margin
37.1%
42.1%
Operating Margin
-92.3%
-19.6%
Net Margin
-90.4%
-19.9%
Revenue YoY
13.8%
-22.7%
Net Profit YoY
-1802.7%
3.4%
EPS (diluted)
$-0.11
$-0.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PACB
PACB
VRA
VRA
Q4 25
$44.6M
$62.3M
Q3 25
$38.4M
$70.9M
Q2 25
$39.8M
$51.7M
Q1 25
$37.2M
$100.0M
Q4 24
$39.2M
$70.5M
Q3 24
$40.0M
$94.0M
Q2 24
$36.0M
$67.9M
Q1 24
$38.8M
$46.2M
Net Profit
PACB
PACB
VRA
VRA
Q4 25
$-40.4M
$-12.4M
Q3 25
$-38.0M
$-4.7M
Q2 25
$-41.9M
$-33.5M
Q1 25
$-426.1M
$-47.0M
Q4 24
$2.4M
$-12.8M
Q3 24
$-60.7M
$5.7M
Q2 24
$-173.3M
$-8.1M
Q1 24
$-78.2M
$-1.9M
Gross Margin
PACB
PACB
VRA
VRA
Q4 25
37.1%
42.1%
Q3 25
41.4%
50.1%
Q2 25
36.9%
44.1%
Q1 25
-3.7%
45.0%
Q4 24
25.6%
54.5%
Q3 24
25.0%
49.7%
Q2 24
16.5%
50.1%
Q1 24
29.1%
37.2%
Operating Margin
PACB
PACB
VRA
VRA
Q4 25
-92.3%
-19.6%
Q3 25
-101.1%
-6.5%
Q2 25
-112.8%
-34.6%
Q1 25
-1154.5%
-23.3%
Q4 24
-390.1%
-11.6%
Q3 24
-160.3%
2.5%
Q2 24
-488.3%
-15.6%
Q1 24
-209.6%
-3.6%
Net Margin
PACB
PACB
VRA
VRA
Q4 25
-90.4%
-19.9%
Q3 25
-98.9%
-6.6%
Q2 25
-105.4%
-64.8%
Q1 25
-1146.8%
-47.0%
Q4 24
6.0%
-18.2%
Q3 24
-151.9%
6.1%
Q2 24
-481.3%
-12.0%
Q1 24
-201.4%
-4.0%
EPS (diluted)
PACB
PACB
VRA
VRA
Q4 25
$-0.11
$-0.44
Q3 25
$-0.13
$-0.17
Q2 25
$-0.14
$-1.20
Q1 25
$-1.44
$-1.62
Q4 24
$-0.44
$-0.46
Q3 24
$-0.22
$0.19
Q2 24
$-0.64
$-0.26
Q1 24
$-0.29
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PACB
PACB
VRA
VRA
Cash + ST InvestmentsLiquidity on hand
$279.5M
$10.7M
Total DebtLower is stronger
$10.0M
Stockholders' EquityBook value
$5.3M
$128.1M
Total Assets
$784.1M
$243.7M
Debt / EquityLower = less leverage
0.08×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PACB
PACB
VRA
VRA
Q4 25
$279.5M
$10.7M
Q3 25
$298.7M
$15.2M
Q2 25
$314.7M
$11.3M
Q1 25
$343.1M
$30.4M
Q4 24
$389.9M
$13.7M
Q3 24
$471.1M
$44.1M
Q2 24
$509.8M
$55.2M
Q1 24
$561.9M
$77.3M
Total Debt
PACB
PACB
VRA
VRA
Q4 25
$10.0M
Q3 25
$10.0M
Q2 25
Q1 25
$0
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
PACB
PACB
VRA
VRA
Q4 25
$5.3M
$128.1M
Q3 25
$36.1M
$140.5M
Q2 25
$61.5M
$146.0M
Q1 25
$91.6M
$179.0M
Q4 24
$506.6M
$225.2M
Q3 24
$453.1M
$242.5M
Q2 24
$492.7M
$245.9M
Q1 24
$649.0M
$259.9M
Total Assets
PACB
PACB
VRA
VRA
Q4 25
$784.1M
$243.7M
Q3 25
$803.2M
$266.2M
Q2 25
$825.5M
$267.9M
Q1 25
$860.8M
$306.7M
Q4 24
$1.3B
$359.0M
Q3 24
$1.5B
$379.2M
Q2 24
$1.5B
$368.7M
Q1 24
$1.7B
$380.8M
Debt / Equity
PACB
PACB
VRA
VRA
Q4 25
0.08×
Q3 25
0.07×
Q2 25
Q1 25
0.00×
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PACB
PACB
VRA
VRA
Operating Cash FlowLast quarter
$-19.1M
$-4.0M
Free Cash FlowOCF − Capex
$-19.9M
$-4.5M
FCF MarginFCF / Revenue
-44.6%
-7.2%
Capex IntensityCapex / Revenue
1.9%
0.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-114.1M
$-13.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PACB
PACB
VRA
VRA
Q4 25
$-19.1M
$-4.0M
Q3 25
$-18.7M
$-5.4M
Q2 25
$-29.4M
$-17.9M
Q1 25
$-44.1M
$21.7M
Q4 24
$-30.6M
$-22.6M
Q3 24
$-45.5M
$1.4M
Q2 24
$-54.3M
$-14.5M
Q1 24
$-75.7M
$26.9M
Free Cash Flow
PACB
PACB
VRA
VRA
Q4 25
$-19.9M
$-4.5M
Q3 25
$-18.8M
$-6.1M
Q2 25
$-29.9M
$-19.8M
Q1 25
$-45.4M
$17.3M
Q4 24
$-32.3M
$-25.0M
Q3 24
$-46.3M
$-1.4M
Q2 24
$-55.7M
$-15.4M
Q1 24
$-79.6M
$25.7M
FCF Margin
PACB
PACB
VRA
VRA
Q4 25
-44.6%
-7.2%
Q3 25
-48.9%
-8.7%
Q2 25
-75.3%
-38.3%
Q1 25
-122.3%
17.3%
Q4 24
-82.3%
-35.5%
Q3 24
-115.7%
-1.5%
Q2 24
-154.8%
-22.7%
Q1 24
-205.0%
55.7%
Capex Intensity
PACB
PACB
VRA
VRA
Q4 25
1.9%
0.7%
Q3 25
0.2%
1.0%
Q2 25
1.4%
3.6%
Q1 25
3.7%
4.3%
Q4 24
4.1%
3.4%
Q3 24
2.0%
3.0%
Q2 24
4.1%
1.3%
Q1 24
10.0%
2.6%
Cash Conversion
PACB
PACB
VRA
VRA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-12.93×
Q3 24
0.25×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

VRA
VRA

Bags$23.9M38%
Indirect$12.6M20%
Transferred At Point In Time$12.2M20%
Accessories$7.2M12%
Home$3.5M6%
Apparel Footwear$1.8M3%
Other Products$1.5M2%

Related Comparisons